2558

(BCG)
2 (HBV)
--
3 (DTwP)

BCG
HBV1

(HBV2)

6 9 12

DTwP-HB1 DTwP-HB2 DTwP-HB3

OPV1
OPV2
( IPV1) ( IPV2)

4 (OPV)
6 (JE)

13 (HPV)

OPV3

4-6

11-12

DTwP 2 Td
10
OPV 2
MMR2
MBV JE3
( Live JE2)

DTaP1

DTaP2

DTaP3

DTaP 1

IPV1

IPV2

IPV3

Hib1

Hib2

Hib3

(IPV4)
Live JE 1, 2
(Hib4)

PCV1
Rota1

OPV 1

--
(DTaP, Tdap)
4 (IPV)
6 (Live JE)
7 (Hib)
8 (HAV)
9 (VZV)
--- (MMRV)
10 (Influenza)
11 (PCV)
3

DTwP 1
MMR1
MBV JE1, JE2 4
( Live JE1)

--5 (MMR)

12 (Rota)

18

PCV2
Rota2

9 12

18

4-6

DTaP 2
Tdap
IPV5

11-12

Tdap
Td 10

HAV 2 6-12
VZV2
VZV1 ( MMRV1)
( MMRV2)
Influenza 6 -18 ( 6-24 ) 2 4
(PCV3)
PCV4
Rota3
( Pentavalent)
HPV 2
6-12

 1.
1. 0.1 .
2.
3. -
2.
1. 3
6
2. HBsAg 3
1-2 6
1 12 . 2 3 1 6
3. HBsAg ( HBeAg
) HBIG 0.5 . 12 . 1
HBIG
HBIG 2 1-2 3
6
HBIG 1 12 . 2
1 3 6
4. HBsAg HBIG
7
5.
--- (DTP-HB) 2, 4, 6
HBsAg HBIG
1 ( 5 )
6. 11
0, 1, 6 11-15
HBVax ProTM ( MSD) 2 0 4-6
1.0 .
7. HBsAg HBsAg
anti-HBs 9-18
3. --
1. (DTaP) (DTwP)
2. DTaP 2, 4, 6

3. 18 DTwP DTaP
4. 4-6 DTwP, DTaP Tdap
5. 11-12 Td Tdap Tdap
4-6 Td 10
6. Tdap 1 TT Td
Td 10
4.
1.
2. 2 3
5 ( )
3. OPV

4. 4 18
5. --
1. 9-12 2 4-6
( 9 )
1 ( 12 )
1
2. 2 2
3. 6

2 2 3
9 2 12 3
4-6
4. --
--- (MMRV)
1-12 MMRV 4-6

MMRV 12-23
MMR VZV
MMRV MMR 1
VZV 3
6.
1. (inactivated vaccine) 2 mouse-brain
derived vaccine (MBV) P3
vero cell (JEVACTM) 3 9-18
4 1 MBV
3 4-5
2. (live JE) SA 14-14-2 2 2
CD.JEVAXTM 9-12 2 3-12
Chimeric JE (IMOJEVTM) 9-12 2
12-24 live JE MBV

3. MBV live JE vaccine

MBV

live-attenuated JE

1
2-3
4

2 3-24 ()
1 1

()
BMI > 35
2. 9 1

3. 3 0.25 0.5 . ()
11.
1. (invasive disease) (severe)
5
2. 10 (PCV10) 13 (PCV13) 3
2, 4 6 12-15
2
3. 2+1 ( 3 )
2, 4, 12-15
4. 5 PCV7 4
PCV13 1 PCV7 8

2-6
7-11
12-23
2-5
*
2- 6

> 6-18

PCV3 6-8
PCV2 6-8
PCV2 6-8
PCV10 2 PCV13 1

PCV 1 12-15
PCV 1 12-15

PCV13 2 8
PCV13 1

PS-23 1
PCV 8

: PCV = Pneumococcal Conjugate Vaccine

PS-23 = 23-Valent pneumococcal polysaccharide vaccine
*

CSF leak, cochlear implantation

* PCV13 2
PS-23 PCV
PS-23 1
5 PCV PS-23 PS-23
PS-23 PCV

7.
1. conjugate PRP-T 3 2, 4 6
2. 12-18

3. 2
12.
4.
1. monovalent 2 2 4
2. pentavalent 3 2, 4 6

PRP-T
3. 6-15
2-6
0, 2, 4, 12-18
8 4
7-11
0, 2, 12-18
4.
12-24

3
> 24 *
0, 2
5.
*
6. severe combined immune deficiency
(SCID)
8.
1 2 6-12 13.

1. 2 2 (bivalent 16, 18) 4
(quadrivalent 6, 11, 16, 18)
9.
2. 9-26 ( 11-12 ) 3
1. 1 12-18
2. 2 4-6 2 4 0, 1-2 6
3. 15 2 0, 6-12
3
4.
3. 1
5. 26
4. 13 1
6. 4 9-26
10.
1. 6 18 2 11-12 9-26